Weight loss results vary based on individual factors. On average, members lose 5–10% of their body weight within the first six months. Results depend on your adherence to the program, lifestyle changes, and how your body responds to the medication.

Our program emphasizes balanced, nutritious meals tailored to your needs. You’ll receive nutrition guidance focusing on whole foods, lean proteins, fruits, vegetables, and healthy fats. Your provider will offer recommendations based on your preferences and nutritional goals.

High demand for GLP-1 medications like Wegovy, Ozempic, and Zepbound has led to occasional shortages. We work closely with you to minimize disruptions.

After completing the intake process, your provider will reach out within 24 hours to review your information. Telehealth appointments are typically scheduled within 1–2 days, while in-person appointments are usually scheduled within 7–10 days, depending on availability. We prioritize timely and consistent support to meet your needs.

After completing an online intake form, your provider will review your medical history, health goals, and current health status. Together, you’ll create a personalized weight loss plan that includes nutrition, exercise, and medication guidance. Regular follow-ups ensure your plan is adjusted as needed for optimal results.

If you’re transitioning from another weight loss program, your provider will review your current medication and dosing to determine the appropriate transition plan. You may not need to start at the lowest dose.

• Your BMI is 27 or higher.
• You’re an adult (18 years or older).

Check HERE to see if you qualify

• Wegovy
• Ozempic
• Zepbound Pens
• Zepbound Vials

Wegovy® and Ozempic® are both brand names for semaglutide, a GLP-1 receptor agonist. These medications help with weight management by reducing appetite, slowing digestion, and promoting feelings of fullness, which can lead to lower caloric intake. While both contain the same active ingredient, their primary differences lie in their FDA-approved uses and dosing:

• Wegovy is approved for chronic weight management in adults with obesity or those who are overweight with weight-related conditions.
• Ozempic is primarily approved for managing type 2 diabetes but is often prescribed off-label for weight loss.

Mounjaro® and Zepbound™ (tirzepatide) are dual GIP and GLP-1 receptor agonists, combining the effects of both hormones to regulate appetite and improve metabolic health. These medications help reduce hunger and enhance energy expenditure, making them highly effective for weight management and metabolic conditions.

• Mounjaro is FDA-approved for the treatment of type 2 diabetes and is also commonly used off-label for weight loss.
• Zepbound is specifically approved for chronic weight management and offers advanced support for patients with obesity and related health issues.

The most common side effects of GLP-1 receptor agonists are gastrointestinal and generally mild. However, severe side effects are rare but may occur and should be addressed promptly.

Common Side Effects:

• Nausea: Often occurs during the initial weeks of treatment or after dose increases.
• Vomiting: Usually mild but can occur in some individuals.
• Diarrhea: A common side effect that typically subsides over time.
• Constipation: May affect some patients and can be managed with dietary adjustments.

Less Common Side Effects:

• Fatigue: Temporary tiredness may occur, especially during the adjustment period.
• Headache: A possible but uncommon side effect.
• Dizziness: Some individuals may experience lightheadedness.

Severe Side Effects (Rare):

• Severe Nausea or Vomiting: Persistent or debilitating symptoms that interfere with daily activities.
• Pancreatitis: Symptoms include severe abdominal pain that may radiate to the back, nausea, and vomiting.
• Allergic Reactions: Such as rash, itching, swelling, severe dizziness, or difficulty breathing.
• Gallbladder Issues: Signs include severe abdominal pain, especially in the upper right side, and yellowing of the skin or eyes (jaundice).
• Kidney Problems: Symptoms such as decreased urination, swelling in the legs, or fatigue.

If you experience any severe or persistent side effects, contact your provider immediately. Your provider will work with you to adjust your treatment plan or explore alternative options. Regular monitoring is key to ensuring your safety and comfort throughout the program.

These side effects typically lessen as your body adjusts. Your provider will monitor your progress and make adjustments as needed to minimize discomfort.

Yes, the medications offered, including Wegovy®, Ozempic®, Zepbound™, Mounjaro®, and compounded semaglutide, are injectable.

• Wegovy, Ozempic, Zepbound, and Mounjaro: These medications come in pre-filled pens designed for weekly administration, ensuring convenience and accurate dosing.

Zepbound Vial: This medication is provided in a single use vial and requires drawing up the dose with a syringe before injecting. Detailed instructions on preparation and administration will be provided to ensure proper use.

Yes, it’s possible. During your consultation, your provider will carefully review your current medications and medical history to identify any potential interactions.

GLP-1 medications are generally safe to use alongside treatments for conditions such as diabetes and high blood pressure. However, they may require adjustments to existing treatments, such as insulin or other blood sugar-lowering medications, to avoid complications like low blood sugar (hypoglycemia). Regular monitoring ensures your safety and optimal treatment outcomes.

Your provider will work with you to create a comprehensive plan that takes all of your medications and health needs into account.

Our services are cash-based, so insurance does not cover the fee. However, some insurance plans may cover prescribed medications like Wegovy, Ozempic, or Zepbound. We can assist with prior authorizations to help you navigate the insurance process.

Yes! You can use this card to pay for your service as well as your medication.